Novavax Inc NVAX.O provides aCOVID-19vaccine targetingOmicronon Friday He said he was planning to do it. Fourth quarter to accelerate the development of shots to protect against BA.4 and BA.5 subvariants.
On Thursday, the US FDA announced this fall that COVID-19 vaccinemanufacturers will include components tuned to fight the now dominant Omicron BA.4. Recommended to change the design of the booster shot from. BA.5 subvariant.
Novavax provides additional preclinical data on shots adjusted for the rapidly spreading Omicron subvarieties in late summer or fall. I'm expecting.
Trend Story
The story follows the ad
Previous company vaccine The virus strain has not yet been approved in the United States and is currently under review by the US Food and Drug Administration.
(Report by Mrinalika Roy in Bangalore, edited by Shounak Dasgupta)
© 2022 Reuters